These data thus not only help understand lung cancer and therapeutic resistance, but also provide a firm basis for use of combination therapy with anti-PD-1/PD-L1, chemotherapeutic and/or epigenetic drugs to treat lung cancer. This evidence concerns the gene CD274 and lung carcinoma.